Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00206154
Status:
COMPLETED
Last Update Posted:
2009-03-27
First Post:
2005-09-13
Brief Title:
A Comparison of Symbicort pMDI 2 x 16045 μg Bid and Symbicort pMDI 2 x 8045 μg Bid With Formoterol Turbuhaler Budesonide pMDI the Combination of Formoterol Turbuhaler and Budesonide pMDI and Placebo in COPD Patients
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A 6-Month Double-Blind Double-Dummy Randomized Parallel Group Multicenter Efficacy Safety Study of SYMBICORT pMDI 2 x 16045 µg 8045 µg Bid Compared to Formoterol TBH Budesonide pMDI the Combination Placebo in COPD Patients
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare a combination asthma drug Symbicort with its two components budesonide and formoterol taken individually or in combination and with placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease COPD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EurodraCT No 2004-001183-41 | None | None | None |